NCT07250802
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
At risk: Primary completion moved at least 1 year 5 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jan 24, 2033 to Jul 3, 2034 Show 5 more changesShow less
- Enrollment increased: 110 → 210 participants
- Eligibility criteria expanded, about 10 words
- Primary endpoints: details revised at 2 of 5 entries
- Study sites: 39 to 38
- Secondary endpoints: details revised at 29 of 30 entries
- Minor Study sites: 40 to 39v10
- Minor Site details revised at 3 of 40 sitesv9
- Minor Site details revised at 9 of 40 sitesv8
- Minor Site details revised at 7 of 40 sitesv7
Show 5 earlier versionsHide 5 earlier versions
- Minor Site details revised at 2 of 40 sitesv6
- Minor Site details revised at 5 of 40 sitesv5
- Minor Site details revised at 3 of 40 sitesv4
- Minor Study sites: 3 to 40v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Dec 1, 2025 to Dec 4, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (30)
Show 25 moreShow less
Arms and interventions
Participants (Adolescent) aged 12 to less than (\<)18 years will receive zasocitinib Dose A once daily (QD), orally, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib, from Week 16 to Week 208 during the open-label period.
Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib from Week 16 to Week 208 during the open-label period.
Participants in Cohort 1 (Adolescent aged 12 to \<18 years) and Cohort 2 (Children aged 4 to \<12 years) will receive zasocitinib matching placebo QD from Week 1 to Week 16 during the double-blind placebo-controlled period.
Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 208 during the open-label period.
Drugs: Zasocitinib, Placebo
Sites
38 sites in 7 countries
United States 11, China 6, Poland 6, Japan 5, Germany 4, Italy 3, Spain 3